ES2117703T3 - Preparacion de factor viii. - Google Patents

Preparacion de factor viii.

Info

Publication number
ES2117703T3
ES2117703T3 ES93890076T ES93890076T ES2117703T3 ES 2117703 T3 ES2117703 T3 ES 2117703T3 ES 93890076 T ES93890076 T ES 93890076T ES 93890076 T ES93890076 T ES 93890076T ES 2117703 T3 ES2117703 T3 ES 2117703T3
Authority
ES
Spain
Prior art keywords
factor viii
factor preparation
preparation viii
preparation
viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93890076T
Other languages
English (en)
Other versions
ES2117703T5 (es
Inventor
Johann Dr Eibl
Friedrich Dr Elsinger
Herbert Gritsch
Yendra Dr Linnau
Otto Dr Schwarz
Peter Dr Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3501200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2117703(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno AG filed Critical Immuno AG
Publication of ES2117703T3 publication Critical patent/ES2117703T3/es
Application granted granted Critical
Publication of ES2117703T5 publication Critical patent/ES2117703T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA OBTENER UNA PREPARACION FACTOR VIII, SEGURA CONTRA LA ACCION DEL VIRUS Y MUY PURA Y SE CARACTERIZA A TRAVES DE LA COMBINACION DE LAS MEDIDAS A) DEPURAR CROMATOGRAFICAMENTE UNA FRACCION CONTENIENDO FACTOR VIII; B) TRATAR TENSIOACTIVAMENTE UNA SOLUCION ACUOSA DE FACTOR VIII QUE TENGA UNA RELACION ENTRE TENSIOACTIVO/PROTEINA ENTRE 1:1 Y 66:1 Y C) CALENTAR LA PREPARACION DEL FACTOR VIII QUE SE ENCUENTRE EN ESTADO SOLIDO.
ES93890076T 1992-04-24 1993-04-07 Preparacion de factor viii. Expired - Lifetime ES2117703T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT84992 1992-04-24
AT0084992A AT399818B (de) 1992-04-24 1992-04-24 Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation

Publications (2)

Publication Number Publication Date
ES2117703T3 true ES2117703T3 (es) 1998-08-16
ES2117703T5 ES2117703T5 (es) 2005-07-16

Family

ID=3501200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93890076T Expired - Lifetime ES2117703T5 (es) 1992-04-24 1993-04-07 Preparacion de factor viii.

Country Status (18)

Country Link
US (1) US5410022A (es)
EP (1) EP0567448B2 (es)
JP (1) JP2511631B2 (es)
AT (2) AT399818B (es)
AU (1) AU659301B2 (es)
BR (1) BR9301641A (es)
CA (1) CA2094347C (es)
CZ (1) CZ279979B6 (es)
DE (1) DE59308628D1 (es)
DK (1) DK0567448T4 (es)
ES (1) ES2117703T5 (es)
FI (1) FI106468B (es)
HU (1) HU210632B (es)
MX (1) MX9302279A (es)
NO (1) NO307465B1 (es)
PL (1) PL172462B1 (es)
SK (1) SK279750B6 (es)
ZA (1) ZA932843B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
DE4407837C1 (de) * 1994-03-09 1995-08-17 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem alpha¶1¶-Antitrypsin mittels Anionenaustauscher-Chromatographie
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
US20040117862A1 (en) * 2002-03-11 2004-06-17 Cooper Julian D. Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses
EP1848812A4 (en) * 2004-10-01 2011-11-09 Life Technologies Corp SUPPLY BUFFERS, SYSTEMS AND METHODS FOR THE IN VITRO SYNTHESIS OF BIOMOLECULES
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
CN101967188B (zh) * 2010-11-08 2012-11-28 江西博雅生物制药股份有限公司 一种人凝血因子ⅷ的制备工艺
CN114917328B (zh) * 2014-11-05 2025-06-20 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT218391B (de) 1959-01-26 1961-11-27 Anton Daxboeck Vorrichtung zur Sicherung einer Türschloßfalle, insbesondere für Kraftfahrzeuge
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
FR2435832A1 (fr) * 1978-07-21 1980-04-04 Alsthom Cgee Dispositif de connexion electrique
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
ATE36457T1 (de) * 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
DE3432083A1 (de) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
AT388501B (de) * 1987-02-12 1989-07-25 Immuno Ag Verfahren zur herstellung von parenteral verabreichbaren blutprodukten
EP0413687A1 (en) * 1987-05-15 1991-02-27 Alan I. Rubinstein Sequential improved method for treatment of human blood-clotting factor products
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
AT391809B (de) * 1988-01-12 1990-12-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutplasmaprodukten
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
DE3878227D1 (de) * 1988-05-27 1993-03-18 Centre Regional De Transfusion Verfahren zur herstellung eines hochreinen, virusfreien antihaemophiliefaktors mittels chromatographie.
AT397203B (de) * 1988-05-31 1994-02-25 Immuno Ag Gewebeklebstoff
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
EP0367840B1 (de) * 1988-11-05 1993-02-03 Octapharma AG Verfahren zur Herstellung eines hochreinen, nicht infektiösen Antihämophiliefaktors mittels Chromatographie
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
DE3843126C3 (de) * 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
EP0378208B2 (en) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Production method for protein-containing composition
JP3297433B2 (ja) * 1989-06-15 2002-07-02 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド ウイルスで汚染された薬理組成物中のウイルスの不活性化方法
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
US5217737A (en) * 1991-05-20 1993-06-08 Abbott Laboratories Plastic containers capable of surviving sterilization
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
AT398079B (de) * 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
FR2841484B1 (fr) * 2002-06-26 2004-09-10 Boucq De Beaudignies Ghisla Le Dispositif et procede de filtration de l'air et des gaz avec regeneration des particules captees

Also Published As

Publication number Publication date
PL298670A1 (en) 1994-04-05
EP0567448A1 (de) 1993-10-27
FI106468B (fi) 2001-02-15
NO931476L (no) 1993-10-25
SK279750B6 (sk) 1999-03-12
ATE166881T1 (de) 1998-06-15
FI931826L (fi) 1993-10-25
NO307465B1 (no) 2000-04-10
PL172462B1 (pl) 1997-09-30
CA2094347C (en) 2002-06-25
CZ69293A3 (en) 1993-12-15
DK0567448T3 (da) 1999-03-22
EP0567448B1 (de) 1998-06-03
ATA84992A (de) 1994-12-15
FI931826A0 (fi) 1993-04-22
AU3687593A (en) 1993-10-28
JPH069694A (ja) 1994-01-18
AT399818B (de) 1995-07-25
CZ279979B6 (cs) 1995-09-13
HU9301038D0 (en) 1993-06-28
NO931476D0 (no) 1993-04-22
HUT64777A (en) 1994-02-28
US5410022A (en) 1995-04-25
BR9301641A (pt) 1993-10-26
CA2094347A1 (en) 1993-10-25
HU210632B (en) 1995-06-28
JP2511631B2 (ja) 1996-07-03
ES2117703T5 (es) 2005-07-16
MX9302279A (es) 1994-08-31
ZA932843B (en) 1993-11-23
DE59308628D1 (de) 1998-07-09
SK39193A3 (en) 1993-11-10
AU659301B2 (en) 1995-05-11
EP0567448B2 (de) 2005-01-05
DK0567448T4 (da) 2005-05-02

Similar Documents

Publication Publication Date Title
ES2113347T3 (es) Procedimiento para la desactivacion de virus en sangre y en productos de sangre.
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
ES2079176T3 (es) Agente de contraste para ecografia.
ES2123922T3 (es) Utilizacion de un antagonista de substancia p en una composicion cosmetica y composicion obtenida.
MX20055A (es) Procedimiento para la preparacion de una composicion acuosa de ibuprofen y procedimiento para su preparacion.
ES500916A0 (es) Un procedimiento para la preparacion y estabilizacion de una composicion blanqueante acuosa que contiene peroxido de hi-drogeno.
CY1105127T1 (el) Συνθεση για την προληψη καρδιαγγειακων νοσων
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
ES2029809T3 (es) Una composicion de tensioactivo.
ES2129127T3 (es) Composiciones cosmeticas filtrantes que contienen un agente hidrofilo que comprende al menos un radical acido sulfonico.
MX9701514A (es) Limpieza, desinfeccion y preparacion de lentes de contacto.
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
MX9302279A (es) Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.
NO970847L (no) 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
EP0222302A3 (en) Strain of aureobasidium pullulans, preparation process and use
ES2058100T3 (es) Vacuna combinada.
ES499884A0 (es) Procedimiento y dispositivo para la preparacion,sin emision de vapores,de salmuera bruta de cloruro sodico acuosa,con- centrada
ES2034999T3 (es) Procedimiento para tratar termicamente gamma-globulina quimicamente no modificada.
ES2062463T3 (es) Procedimiento de blanqueo de pastas celulosicas quimicas.
ES2176805T3 (es) Empleo de mezclas de productos activos para la obtencion de agentes hipocolesterinemicos.
ES2111752T3 (es) Agente para el tratamiento del cabello.
FR2572286B1 (fr) Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
FR2618677B1 (fr) Composition pharmaceutique destinee a la prevention et au traitement des maladies bacteriennes ou virales

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567448

Country of ref document: ES